Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study

Fineline Cube Aug 10, 2022

China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...

Company

Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut

Fineline Cube Aug 10, 2022

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...

Company Drug

BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study

Fineline Cube Aug 10, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...

Company Drug

Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial

Fineline Cube Aug 10, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...

Company Drug

Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study

Fineline Cube Aug 9, 2022

Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...

Company Deals

Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China

Fineline Cube Aug 9, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment

Fineline Cube Aug 9, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...

Medical Device

GeneoDx Biotech’s Cervical Cancer Screening Kit Wins NMPA Approval

Fineline Cube Aug 9, 2022

Shanghai GeneoDx Biotech Co., Ltd, a medical diagnosis unit of Sinopharm, has announced that it...

Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty and Angelguide Approved in Colombia

Fineline Cube Aug 9, 2022

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced...

Company Drug

HeNan Genuine Biotech Sets Azvudine Price at RMB300 per Bottle for COVID-19 Therapy

Fineline Cube Aug 9, 2022

China-based HeNan Genuine Biotech Co., Ltd has set the price of its COVID-19 therapy azvudine...

Company Deals

Sinotherapeutics Inc. to Raise RMB600m via STAR Board IPO for Generic Drug Expansion

Fineline Cube Aug 9, 2022

Sinotherapeutics Inc., a Shanghai-based generic drug developer, is set to make an initial public offering...

Policy / Regulatory R&D

CDE Issues Q&As on COVID-19 Antiviral Drug Evaluation Criteria

Fineline Cube Aug 9, 2022

The Center for Drug Evaluation (CDE) has published a list of Q&As regarding the non-clinical...

Company Medical Device

NMPA Approves BioFire Diagnostics’ Encephalitis/Meningitis Detection Kit

Fineline Cube Aug 9, 2022

The National Medical Products Administration (NMPA) website indicates that BioFire Diagnostics LLC’s encephalitis/meningitis multiple pathogen...

Company Deals R&D

BioDuro-Sundia and X-Chem Form Long-Term Partnership for Drug Discovery

Fineline Cube Aug 8, 2022

Two China-based companies, the Contract Research, Development, and Manufacturing Organization (CRDMO) BioDuro-Sundia and X-Chem, have...

Company Drug

Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion

Fineline Cube Aug 8, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its...

Company Deals Digital

Hywin Holdings to Acquire Life Infinity for Health Management Expansion

Fineline Cube Aug 8, 2022

China-based wealth management firm Hywin Holdings is set to move into the health management business...

Company Drug

HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint

Fineline Cube Aug 8, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase...

Company Deals

Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV

Fineline Cube Aug 8, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...

Company Drug

Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME

Fineline Cube Aug 8, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Drug

Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma

Fineline Cube Aug 8, 2022

Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has...

Posts pagination

1 … 594 595 596 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.